D. Price

Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial

M. Sanak, C. Griffiths, S. Eldridge, 2015 .

Urinary prostanoids in preschool wheeze

M. Sanak, C. Griffiths, H. Pandya, 2017, European Respiratory Journal.

Treatment guided by fractional exhaled nitric oxide in addition to standard care in 6- to 15-year-olds with asthma: the RAACENO RCT

N. Scott, J. Norrie, G. Scotland, 2022, Efficacy and Mechanism Evaluation.

Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial.

N. Scott, J. Norrie, G. Scotland, 2022, The Lancet. Respiratory medicine.

Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial

M. Sanak, C. Griffiths, S. Eldridge, 2014, The Lancet. Respiratory medicine.

IMPlementing IMProved Asthma self-management as RouTine (IMP2ART) in primary care: study protocol for a cluster randomised controlled implementation trial

Stephanie J. C. Taylor, H. Pinnock, V. Hammersley, 2023, Trials.

Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: a randomised trial (RAACENO)

D. Price, J. Norrie, A. Neilson, 2019, Trials.